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CC BY-NC-ND license (http://creativeAbstract X-ray structure of methyl-CpG binding domain (MBD) of MeCP2, an intrinsically
disordered protein (IDP) involved in Rett syndrome, offers a rational basis for defining the
spatial distribution for most of the sites where mutations responsible of Rett syndrome,
RTT, occur. We have ascribed pathogenicity for mutations of amino acids bearing positively
charged side chains, all located at the protein-DNA interface, as positive charge removal cause
reduction of the MeCP2-DNA adduct lifetime. Pathogenicity of the frequent proline replace-
ments, outside the DNA contact moiety of MBD, can be attributed to the role of this amino acid
for maintaining both unfolded states for unbound MeCP2 and, at the same time, to favor some
higher conformational order for stabilizing structural determinants required by protein activ-
ity. These hypotheses can be extended to transcription repressor domain, TRD, the other
MeCP2-DNA interaction site and, in general, to all the IDP that interact with nucleic acids.
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In girls under the age of 12, Rett syndrome, RTT, occur-
rence is estimated at 1/9000. This pathology has been
associated to mutations in the X-linked MECP2 gene,1 as
patients bearing this neurological disorder always exhibit
modified sequences of methyl-CpG-binding protein 2,
MeCP2. Along the 486 amino acid MeCP2 sequence, thereand hosting by Elsevier B.V. This is an open access article under the
4.0/).
Figure 2 Distribution of missense mutation sites along
MeCP2 sequence (adapted from RettDB). Labels refer to the
most frequent mutations; the corresponding occurrences are
shown in parenthesis.
32 O. Spiga et al.are unambiguous signals confirming the role of the protein
in the interaction with DNA. Indeed, AT-hook domains,
critical for altering chromatin structure, have been delin-
eated in MeCP2 transcription repressor domains, TRD,2e4
together with a methyl-CpG-binding domain, MBD.
Trying to correlate structural aspects of amino acid
changes arising from missense MecP2 mutations with RTT is
not straightforward, as the protein belongs to the class of
intrinsically disordered proteins, IDPs,5 see Fig. 1. In this
respect, it is interesting to note how many other IDPs have
been found involved in neurodegenerative diseases.6
Methods and materials
MECP2 Variation Database (RettBASE),7 a curated database
of all the reported MaCP2 mutations, has been used as a
reference for our bioinformatic survey. The X ray resolved
structure of MaCP2 fragment bound to a 20 bp DNA has been
retrieved from the Protein Data Bank with the PDB ID code
5BT2.8 The structural features of the MeCP2-DNA adduct
has been analyzed with Open source PyMOL v. 1.7.1.0.9
Results and discussion
Among the 4738 records reported in the RettBASE site7 for
all the observed MeCP2 variations, 3377 are related to
missense mutations that are unevenly distributed along the
protein sequence, as they are found mainly in 78e162 MBD,
207e255 TRD1 and 271e310 TRD2 fragments of MeCP2
sequence, see Fig. 2. However, as only a small fraction of
the latter sequence changes has been unequivocally asso-
ciated to RTT, we have confined our analysis to the 19
MeCP2 missense mutation sites verified by accurate clinicalFigure 1 Percent average amino acid occurrences in globular pro
in MeCP2 respectively coloured in blue, red and green (adapted frinvestigations and considered by UniProtKB10 database
(https://www.uniprot.org/uniprot/P51608). Thus, from
the latter database 11, 2 and 3 mutation sites are
identified respectively in 78e162 MBD, 207e255 TRD1 and
271e310 TRD2 fragments of MeCP2 sequence, suggesting
that DNA interacting moieties of the protein are primarily
relevant for inducing RTT, see Table 1. It is interesting to
note that, among the 19 UniprotKb defined mutation sites,
Pro and Arg substitutions occur, by far, as the most frequent
ones, as the latter amino acids are replaced five times
each. This finding is consistent with the critical role of Proteins, intrinsically disordered proteins adapted from ref (X) and
om Uversky 2009).
Table 1 a) Mutation sites according to UniProtKB. b) Amino acids located in wild-type MeCP2. Yellow, blue and green boxes
refer to MBD, TRD1 and TRD2 respectively. Amino acids highlighted in bold red characters are the ones that are present in the
protein-DNA interface. c) Amino acid replacements with their frequency in parenthesis as retrieved from RettBASE.
Figure 3 Pymol representation of MBD structure (PDB ID
code 5BT2). Amino acids that are involved in pathogenic mu-
tations are shown with spheres; yellow atoms refer to inter-
facial amino acids; prolines are highlighted in violet. Water
molecules bridging S134 and T158 to DNA chains are shown in
cyan.
Structural investigation of Rett 33for maintaining unfolded states in IDP5 and with the high
relevance of Arg in establishing suitable lifetimes for
protein-DNA adducts.11
Recently, a MBD-DNA adduct has been structurally
characterized by X-ray crystallography12 and the corre-
sponding structure, deposited in the Protein Data Bank8
with the ID code 5BT2, yields a powerful tool for deci-
phering the roles of the observed mutations in relation to
RTT appearance. Thus, by using PISA database13 amino
acids that are located at MeCP2-DNA interface can be
identified. The presence of two Arg and one Lys at the
MeCP2-DNA interface confirms how critical is the removal
of positively charged side chains in this protein moiety, see
Table 1. Table 1 shows also that replacements of Ser and
Thr with amino acids whose side chains are not bearing
hydroxyl groups, interfere with interface hydration. Inter-
facial water molecules, indeed, determining the dynamics
of protein-DNA approach,11 strongly modulate the latter
interaction.
Fig. 3 summarizes the structural distribution of patho-
genic mutations in MBD, underlining the role of positively
charged amino acids, particularly of Arg, in the binding to
DNA. Pro, the other very frequently mutated amino acid in
RTT, is outside the MBD-DNA contact region to the drive the
local folding that is due to trigger the physiological inter-
molecular interaction. These structural features can be
used for interpreting the role of Arg, Lys and Proin TRD1 and
TRD2 mutation sites, see Table 1. Thus, Arg210, Lys305 and
34 O. Spiga et al.Arg306 replacements most likely affect MeCP2 interaction
with DNA. Similarly, Pro225 and Pro302 mutations could
inhibit the transient folding that is required for MeCP2
function.
For alleviating RTT effects, among all the so far pro-
posed therapeutic strategies,14 only few efforts exhibit
some effectiveness.15 Possibly, CRISPR-Cas9 will provide in
a near future more reliable answers to RTT damages. Thus,
in future genome-editing procedures16 our present obser-
vations suggest that in all neuropathologies involving DNA
binding IDPs, particular care to protect Arg, Lys and Pro
from mutations should be taken.
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